Literature DB >> 12686738

Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling.

Shokei Kim1, Hiroshi Iwao.   

Abstract

Mitogen-activated protein kinases (MAP kinases), including extracellular signal-regulated kinase (ERK), c-Jun NH(2)-terminal kinase (JNK), and p38, play a central role in cellular responses by various stress stimuli such as cell proliferation, apoptosis, migration, or gene expression. Furthermore, activator protein-1 (AP-1), a transcription factor which can be activated by MAP kinases, also is involved in a variety of celllar responses, as well as MAP kinases. MAP kinases and AP-1 are significantly activated in vascular tissues by hypertension, angiotensin II, or balloon injury. We have made dominant negative mutants of MAP kinases or c-Jun, to specifically inhibit in vivo activation of MAP kinases or AP-1. Vascular gene transfer of each dominant negative mutant of MAP kinases or c-Jun prevents intimal hyperplasia after balloon injury, which is associated with the inhibition of smooth muscle cell proliferation in the intima and the media and probably also associated with inhibition of smooth muscle cell migration. However, in vitro findings on cultured vascular smooth muscle cells suggest that the molecular mechanism underlying inhibition of intimal hyperplasia may be different among each dominant negative mutant of MAP kinases and c-Jun. MAP kinases and c-Jun seem to be the promising therapeutic target for vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12686738     DOI: 10.1254/jphs.91.177

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  15 in total

Review 1.  Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury.

Authors:  Christopher A Papaharalambus; Kathy K Griendling
Journal:  Trends Cardiovasc Med       Date:  2007-02       Impact factor: 6.677

2.  Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia.

Authors:  Paloma H Giangrande; JianXin Zhang; Alice Tanner; Andrea D Eckhart; Rachel E Rempel; Eran R Andrechek; Juliana M Layzer; Janelle R Keys; Per-Otto Hagen; Joseph R Nevins; Walter J Koch; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-25       Impact factor: 11.205

3.  Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3.

Authors:  F Strittmatter; S Walther; C Gratzke; J Göttinger; C Beckmann; A Roosen; B Schlenker; P Hedlund; K E Andersson; C G Stief; M Hennenberg
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

4.  Thrombin induced connective tissue growth factor expression in rat vascular smooth muscle cells via the PAR-1/JNK/AP-1 pathway.

Authors:  Wen-chin Ko; Bing-chang Chen; Ming-jen Hsu; Chia-ti Tsai; Chuang-ye Hong; Chien-huang Lin
Journal:  Acta Pharmacol Sin       Date:  2012-01       Impact factor: 6.150

5.  P21-activated protein kinase (PAK2)-mediated c-Jun phosphorylation at 5 threonine sites promotes cell transformation.

Authors:  Tingting Li; Jishuai Zhang; Feng Zhu; Weihong Wen; Tatyana Zykova; Xiang Li; Kangdong Liu; Cong Peng; Weiya Ma; Guozheng Shi; Ziming Dong; Ann M Bode; Zigang Dong
Journal:  Carcinogenesis       Date:  2010-12-22       Impact factor: 4.944

6.  Mixed-lineage kinase 3 deficiency promotes neointima formation through increased activation of the RhoA pathway in vascular smooth muscle cells.

Authors:  Vidya Gadang; Eddy Konaniah; David Y Hui; Anja Jaeschke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-01       Impact factor: 8.311

7.  Trypanosoma cruzi infection activates extracellular signal-regulated kinase in cultured endothelial and smooth muscle cells.

Authors:  Shankar Mukherjee; Huan Huang; Stefka B Petkova; Chris Albanese; Richard G Pestell; Vicki L Braunstein; George J Christ; Murray Wittner; Michael P Lisanti; Joan W Berman; Louis M Weiss; Herbert B Tanowitz
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.

Authors:  Rathai Anandanadesan; Qiaoke Gong; Galina Chipitsyna; Agnes Witkiewicz; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2007-11-17       Impact factor: 3.452

9.  Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells.

Authors:  Navdeep Chehl; Qiaoke Gong; Galina Chipitsyna; Tamer Aziz; Charles J Yeo; Hwyda A Arafat
Journal:  J Gastrointest Surg       Date:  2009-10-09       Impact factor: 3.452

10.  Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

Authors:  Liliana Moreno-Vinasco; Mardi Gomberg-Maitland; Michael L Maitland; Ankit A Desai; Patrick A Singleton; Saad Sammani; Lee Sam; Yang Liu; Aliya N Husain; Roberto M Lang; Mark J Ratain; Yves A Lussier; Joe G N Garcia
Journal:  Physiol Genomics       Date:  2008-02-26       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.